17.42

4.18% -0.76

Ideaya Biosciences Inc (IDYA)

Overview News Price History Option Chain Financials Discussions Forecast

Ideaya Biosciences Inc stock is traded at $17.42, with a volume of 944.32K. It is down -4.18% in the last 24 hours and up +10.39% over the past month. IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Previous Close:

$18.18

Open:

$18.04

24h Volume:

944.32K

Relative Volume:

0.79

Market Cap:

$1.83B

Revenue:

$23.38M

Net Income/Loss:

$-155.22M

P/E Ratio:

-7.9543

EPS:

-2.19

Net Cash Flow:

$-134.36M

1W Performance:

-16.77%

1M Performance:

+10.39%

6M Performance:

-44.31%

1Y Performance:

-57.14%

1-Day Range:

$17.33

$18.77

1-Week Range:

$16.82

$21.13

52-Week Range:

$13.45

$44.42

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Name

Ideaya Biosciences Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

650-443-6209

Address

5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA

Employee

131

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

IDYA's Discussions on Twitter

Compare IDYA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IDYA Ideaya Biosciences Inc	17.42	1.83B	23.38M	-155.22M	-134.36M	-2.19
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Initiated	Stephens	Overweight
Nov-05-24	Downgrade	Leerink Partners	Outperform → Market Perform
Oct-24-24	Initiated	UBS	Buy
Oct-15-24	Initiated	Cantor Fitzgerald	Overweight
Jul-08-24	Initiated	Mizuho	Outperform
Mar-08-24	Initiated	BTIG Research	Buy
Aug-08-23	Initiated	SVB Securities	Outperform
May-24-23	Initiated	Goldman	Buy
Apr-24-23	Upgrade	Stifel	Hold → Buy
Mar-23-23	Initiated	Berenberg	Buy
Feb-28-23	Initiated	RBC Capital Mkts	Outperform
Dec-28-22	Initiated	CapitalOne	Overweight
Oct-27-22	Initiated	Citigroup	Buy
Aug-15-22	Downgrade	Stifel	Buy → Hold
Jul-18-22	Resumed	Oppenheimer	Outperform
Mar-10-22	Upgrade	Stifel	Hold → Buy
Sep-23-21	Initiated	Stifel	Hold
Jun-04-21	Resumed	Robert W. Baird	Outperform
Mar-11-21	Initiated	Guggenheim	Buy
Oct-07-20	Initiated	Wedbush	Outperform
Sep-01-20	Initiated	Northland Capital	Outperform
Jul-13-20	Upgrade	JP Morgan	Neutral → Overweight
Jun-17-20	Reiterated	H.C. Wainwright	Buy
Apr-06-20	Initiated	H.C. Wainwright	Buy
Mar-13-20	Initiated	ROTH Capital	Buy
Oct-17-19	Initiated	Oppenheimer	Outperform
Sep-10-19	Initiated	Robert W. Baird	Outperform
Jun-17-19	Initiated	Citigroup	Buy
Jun-17-19	Initiated	JP Morgan	Neutral
Jun-17-19	Initiated	Jefferies	Buy

View All

Ideaya Biosciences Inc Stock (IDYA) Latest News

May 07, 2025

Ideaya Biosciences (IDYA) Faces Market Reaction Following FDA Le - GuruFocus

May 07, 2025

IDEAYA Biosciences Reports Q1 2025 Financial Results - TipRanks

May 07, 2025

May 06, 2025

IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029 - marketscreener.com

May 06, 2025

IDEAYA gets approval to begin trial for its antibody drug conjugate in solid tumors - Seeking Alpha

May 06, 2025

Ideaya Biosciences (IDYA) Advances with FDA Approval for IDE849 Trial | IDYA Stock News - GuruFocus

May 06, 2025

IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid Tumors - marketscreener.com

May 06, 2025

FDA clears IDEAYA’s Phase 1 trial for new cancer drug By Investing.com - Investing.com South Africa

May 06, 2025

Ideaya Biosciences (IDYA) Achieves Major Milestones in Oncology Programs | IDYA Stock News - GuruFocus

May 06, 2025

IDEAYA Secures FDA Breakthrough Status as 300+ Patient Melanoma Trial Advances Toward Key 2025 Readout - Stock Titan

May 06, 2025

Breakthrough Cancer Drug IDE849 Gets FDA Green Light: Early Data Shows Promise in Multiple Tumors - Stock Titan

May 06, 2025

May 05, 2025

IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations - Barchart.com

May 05, 2025

IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma - Barchart.com

May 05, 2025

Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey

May 05, 2025

May 02, 2025

Trading (IDYA) With Integrated Risk Controls - news.stocktradersdaily.com

May 02, 2025

Apr 30, 2025

Nothing is Better Than Ideaya Biosciences Inc (IDYA) stock at the moment - Sete News

Apr 30, 2025

Apr 29, 2025